Home>Topics>Stocks>AstraZeneca PLC ADR

AstraZeneca PLC ADR AZN

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. New clinical trial format may boost cancer drug development

      Headlines

      Thu, 17 Apr 2014

      patients so the traditional method of clinical trial design is too expensive, time-consuming and inefficient. AstraZeneca ( AZN ) will supply up to twelve experimental drugs that will be given to patients who do not show one of twenty-one

    2. New kind of trial aims to speed cancer drug development

      Headlines

      Wed, 16 Apr 2014

      * AstraZeneca , Pfizer, UK charity link in multi-drug trial

    3. UPDATE 2-Danske Bank fined by Nasdaq OMX over AstraZeneca share trading

      Headlines

      Wed, 16 Apr 2014

      * Danske Bank to pay 500,000 SEK for breaching trading rules

    4. AstraZeneca India unit sets floor price for stock delisting

      Headlines

      Fri, 11 Apr 2014

      April 11 (Reuters) - AstraZeneca Pharma India Ltd, a unit of British drugmaker AstraZeneca Plc, said on Friday the floor price for its delisting from the Indian stock exchanges had been set at 854.1 rupees a share.

    5. French plan to allow generics alarms Big Pharma

      Headlines

      Thu, 10 Apr 2014

      only apply to retail pharmacies. 40% of biotech prescriptions are filled in hospitals. ( OTCQX:RHHBY ) ( AMGN ) ( NVS ) ( SNY ) ( LLY ) ( PFE ) ( BMY ) ( MRK ) ( GSK ) ( JNJ ) ( HSP ) ( ABBV ) ( AZN ) ( OTCPK:BAYRY ) Post your comment!

    6. The Sector Is Fairly Valued, but These Stocks Are Not

      Video Reports

      Thu, 10 Apr 2014

      s a great place to be, but from a valuation perspective a couple names we're concerned about are [TICKER: AZN ] AstraZeneca and [TICKER:BAYRY] Bayer. And then when we flip to the other side, names we think are undervalued, really

      AZN AstraZeneca found at 0:33

      be, but from a valuation perspective a couple names we're concerned about are [TICKER: AZN ] AstraZeneca and [TICKER:BAYRY] Bayer. And then when we flip to the other side, names we think are undervalued, really Sanofi comes to the top
    7. Critical Shortage Of Injectables Create Opportunity For Drugmakers

      Headlines

      Wed, 9 Apr 2014

      By Kapitall : Of the 65 drug shortages listed by the Food and Drug Administration, more than 40 are of the generic sterile injectable variety. Nitroglycerin, used intravenously to treat hypertension and assorted heart conditions, is one of those drugs. Last year, two manufacturers -- Hospira ( HSP

    8. How One Retiree Is Muddling Through Dividend Investing: Part IX - My Dividend Investment Business Plan

      Headlines

      Wed, 9 Apr 2014

      By Martin Rice : I Never Did It On February 10, 2013, I published Part IV of this series. Bob Wells, in one of his many helpful comments, said: "Develop a business plan for your portfolio clearly defining your criteria for buying, selling or trimming a position. Here's the link to mine " ...

    9. Sell Ranbaxy And Buy AstraZeneca : Good Chance Nexium Generic Launch Delayed

      Headlines

      Sat, 5 Apr 2014

      in May 27 2014 (as per settlement agreement with AstraZeneca ( AZN ) ). In 2013, Nexium generated $2.1b in annual ..... to launch Nexium Generics timely and in that case AstraZeneca would be able to restore their brand exclusivity for

    10. China still bright for Big Pharma

      Headlines

      Wed, 2 Apr 2014

      emerge as the globe's second largest pharmaceutical behind the U.S. by 2016 on the basis of $165B in sales. ( SNY ) ( LLY ) ( NVS ) ( AZN ) ( PFE ) ( BMY ) ( JNJ ) ( OTCPK:BAYRY ) ( OTCQX:RHHBY ) ( NVO ) ( ABBV ) Post your comment!

    « Prev12345Next »
    Content Partners